ZUG, Switzerland, May 30, 2024 Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members.
Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation4D-150 PRISM randomized Phase 2 Dose Expansion Cohort 24-week encore results to be presented in a poster .
The molecule is being evaluated in 2 phase 3 clinical trials for wet AMD and is administered via intravitreal injection in combination with standard-of-care anti–VEGF-A therapy.
The phase 2b trial showed a statistically significant improvement of BCVA at week 52 in both the high-dose and low-dose MCO-010 cohorts compared with sham.